|

EP0062 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Ellipses Pharma1

Indications

  • Metastatic Breast Cancer1
  • Hormone Receptor Positive HER-2 Negative Breast Cancer1
  • Hormone Receptor Positive Breast Cancer1
  • Breast Cancer1
  • Cancer1

New Haven, Connecticut1 trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.